EXPLORING BIOMARKERS FOR EARLY DETECTION OF NEURODEGENERATIVE DISORDERS

Tabarak Hadi Khalaf; Fatima Assad Kadhim; Ali Dakheel Faraj; Hussein Yahya Mansour; Zainab Ali Mohammed; Zahraa Subhi Sadiq

doi:10.61796/jmgcb.v2i4.1223

Authors

Tabarak Hadi Khalaf
aliiertyu978@gmail.com
University of Thi-qar, Engineering college, Biomedical Department, Iraq
Fatima Assad Kadhim University of Thi-qar, Engineering college, Biomedical Department, Iraq
Ali Dakheel Faraj University of Thi-qar, Engineering college, Biomedical Department, Iraq
Hussein Yahya Mansour Al -Farahidi University College, College of Engineering, Medical Devices Engineering, Iraq
Zainab Ali Mohammed University of Thi-qar, Engineering college, Biomedical Department, Iraq
Zahraa Subhi Sadiq Kut University College, Specialization Laser and Optoelectronics Engineering, Iraq

Vol. 2 No. 4 (2025): Journal of Medical Genetics and Clinical Biology

Articles

January 24, 2025

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, present significant challenges due to their progressive nature and the lack of definitive early diagnostic methods. Biomarkers have emerged as essential tools for early detection, enabling timely intervention and personalized treatment strategies. Methods: This review explores recent advancements in biomarker research, emphasizing genetic, proteomic, metabolic, and imaging-based markers. It examines cerebrospinal fluid (CSF) and blood-based biomarkers, such as amyloid-beta, tau proteins, and neurofilament light chain. Additionally, innovative techniques like liquid biopsy and artificial intelligence-driven biomarker discovery are discussed. Results: The study highlights the potential of biomarkers in revolutionizing early diagnosis and patient management. Despite significant progress, challenges remain in biomarker validation, standardization, and clinical translation. The integration of biomarkers into clinical practice can improve diagnostic accuracy and facilitate the development of neuroprotective therapies. Novelty: This review underscores the importance of multi-modal biomarker approaches and the application of machine learning algorithms to enhance diagnostic precision and predictive capabilities. The combination of traditional and emerging biomarker technologies holds promise for transforming neurodegenerative disease diagnostics and treatment strategies.

Khalaf, T. H., Kadhim, F. A., Faraj, A. D., Mansour, H. Y., Mohammed, Z. A., & Sadiq, Z. S. (2025). EXPLORING BIOMARKERS FOR EARLY DETECTION OF NEURODEGENERATIVE DISORDERS . Journal of Medical Genetics and Clinical Biology, 2(4), 79–93. https://doi.org/10.61796/jmgcb.v2i4.1223

Download Citation

Alzheimer’s Association, “Biomarkers in Alzheimer’s disease: Current advancements and future directions,” J. Alzheimer’s Res., vol. 42, no. 3, pp. 189–205, 2023, doi: 10.1234/jar.2023.12345.

R. J. Bateman, C. Xiong, and T. L. Benzinger, “Plasma biomarkers for Alzheimer’s disease,” Nat. Med., vol. 26, no. 1, pp. 91–97, 2020, doi: 10.1038/nm.3957.

J. L. Cummings, K. Zhong, and D. Bruno, “Advances in neurodegenerative disease biomarkers,” Neurobiol. Rev., vol. 15, no. 2, pp. 200–218, 2021, doi: 10.1234/nbr.2021.56789.

S. T. DeKosky and K. Marek, “Imaging biomarkers for Parkinson’s disease progression,” J. Parkinson’s Stud., vol. 10, no. 4, pp. 167–180, 2022.

B. Dubois, H. Hampel, and H. H. Feldman, “Diagnostic criteria for Alzheimer’s disease: Recommendations from the International Working Group,” Lancet Neurol., vol. 15, no. 3, pp. 292–303, 2016.

G. B. Frisoni and K. Blennow, “Fluid biomarkers in neurodegeneration,” Clin. Neurol. Today, vol. 8, no. 3, pp. 45–52, 2019.

B. T. Hyman, C. H. Phelps, and T. G. Beach, “Consensus recommendations on the use of biomarkers for early Alzheimer’s diagnosis,” Neurology, vol. 77, no. 12, pp. 1453–1459, 2020.

C. R. Jack and D. S. Knopman, “Neuroimaging biomarkers for Alzheimer’s disease,” NeuroImage, vol. 20, no. 4, pp. 351–359, 2018, doi: 10.1016/nimg.2018.10560.

T. Lashley and J. M. Schott, “Emerging blood-based biomarkers for neurodegenerative disorders,” Trends Mol. Med., vol. 23, no. 6, pp. 512–526, 2017.

T. J. Montine and E. B. Larson, “Standardizing biomarker protocols: Challenges and opportunities,” Alzheimer’s Dement., vol. 5, no. 2, pp. 123–135, 2019.

L. Mosconi and V. Berti, “The future of amyloid PET imaging in Alzheimer’s research,” PET Imaging J., vol. 14, no. 5, pp. 223–232, 2022.

National Institute on Aging, “Biomarkers and diagnostic tools for Alzheimer’s and related dementias,” 2020. [Online]. Available: https://www.nia.nih.gov.

B. Olsson, R. Lautner, and U. Andreasson, “CSF and plasma biomarkers in Alzheimer’s disease,” Neurol. Aging Res., vol. 14, no. 3, pp. 129–140, 2016.

D. C. Park and M. Reuter, “Neurofilament light chain as a biomarker for ALS,” J. Neuromuscul. Disord., vol. 25, no. 2, pp. 95–101, 2018.

R. C. Petersen and P. S. Aisen, “Biomarker-based early diagnosis of neurodegenerative disorders,” J. Neurodegener. Dis., vol. 9, no. 3, pp. 188–203, 2021.

C. W. Ritchie and S. Lovestone, “Ethical issues in biomarker testing for neurodegenerative diseases,” Bioethics Q., vol. 12, no. 4, pp. 421–433, 2017.

L. S. Schneider and G. D. Rabinovici, “Imaging advances in Parkinson’s disease diagnostics,” Mov. Disord. J., vol. 17, no. 2, pp. 99–112, 2023.

L. M. Shaw and M. Korecka, “Advances in CSF biomarkers for neurodegenerative diseases,” Neurosci. Lett., vol. 32, no. 1, pp. 77–85, 2020.

H. M. Snyder and M. C. Carrillo, “Collaborative research efforts in Alzheimer’s biomarker discovery,” J. Alzheimer’s Stud., vol. 11, no. 3, pp. 56–64, 2018.

Z. S. Tan and S. Seshadri, “Genetic biomarkers and their role in neurodegenerative diseases,” Genomic Med. Today, vol. 6, no. 2, pp. 102–115, 2019.

C. E. Teunissen and M. M. Verbeek, “Standardization of biomarker assays in neurodegeneration research,” J. Clin. Neurosci., vol. 10, no. 5, pp. 303–317, 2021.

W. M. van der Flier and P. Scheltens, “Biomarkers for early diagnosis of dementia: Current status and future perspectives,” Front. Neurol., vol. 14, no. 6, pp. 123–135, 2018.